Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 1, 2009, Pages 83-89

  Redden, Laura ^a   Delbello, Melissa ^b   Wagner, Karen Dineen ^c   Wilens, Timothy E ^d   Malhotra, Shishuka ^e   Wozniak, Patricia ^f   Vigna, Namita V ^a   Greco, Nicholas ^a   Kovacs, Xenia ^a   Abi Saab, Walid ^a   Saltarelli, Mario ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Advanced Clinical Research Services ^*  (United States)

^f Advanced Clinical Research Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROATE SEMISODIUM;

ADOLESCENT; AMMONIA BLOOD LEVEL; ARTICLE; BEHAVIOR; BIPOLAR I DISORDER; CAREGIVER; CHILD; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA; MIXED MANIA AND DEPRESSION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TREMOR; UPPER ABDOMINAL PAIN; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ADOLESCENT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CHILD; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; VALPROIC ACID;

EID: 60949085968     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0106     Document Type: Article

References (36)

1. Abbott Laboratories: Depakote ER (Divalproex sodium extended-release tablets) prescribing information. North Chicago IL 60064.
2. th edition, Text Revision (DSMIV-TR). Washington DC: American Psychiatric Association, 2000, pp 85-93.
3. Apostol G, Cady RK, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM, Saltarelli M: Divalproex extended-release in adolescent migraine prophylaxis: Results of a randomized, double-blind, placebo-controlled study. Headache 48:1012-1025, 2008.
4. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, et al.: Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 271:918-924, 1994.
5. Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M: A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 67:1501-1510, 2006.
6. Brannan AM HC, Bickman L: The Caregiver Strain Questionnaire: Measuring the impact on the family of living with a child with serious emotional disturbance. J Emotional and Behav Disord 5:212-222, 1997.
7. Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 46:687-700, 2007.
8. da Fonseca-Wollheim F: Preanalytical increase of ammonia in blood specimens from healthy subjects. Clin Chem 36(8 Pt 1):1483-1487, 1990.
9. Doyle AE, Wilens TE, Kwon A, Seidman LJ, Faraone SV, Fried R, Swezey A, Snyder L, Biederman J: Neuropsychological functioning in youth with bipolar disorder. Biol Psychiatry 58:540-548, 2005.
10. Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW: Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 49:1-10, 2002.
11. Guy W (ed.) Clinical Global Impressions in Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rockville (Maryland): US National Institute of Mental Health, 1976.
12. Howanitz JH, Howanitz PJ, Skrodzki CA, Iwanski JA: Influences of specimen processing and storage conditions on results for plasma ammonia. Clin Chem 30:906-908, 1984.
13. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-88, 1997.
14. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, Emslie GJ, Weinberg WA, Rush AJ: Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 39:713-720, 2000.
15. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1-100, 1987.
16. Maranda B, Cousineau J, Allard P, Lambert M: False positives in plasma ammonia measurement and their clinical impact in a pediatric population. Clin Biochem 40:531-535, 2007.
17. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M: National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 64:1032-1039, 2007.
18. National Center for Health Statistics. Health, United States, with Chartbook on Trends in the Health of Americans. Hyattsville (Maryland): National Center for Health Statistics, 2006.
19. Pavuluri MN, Henry DB, Carbray JA, Naylor MW, Janicak PG: Divalproex sodium for pediatric mixed mania: A 6-month prospective trial. Bipolar Disord 7:266-273, 2005.
20. Pavuluri MN, O'Connor MM, Harral EM, Moss M, Sweeney JA. Impact of neurocognitive function on academic difficulties in pediatric bipolar disorder: A clinical translation. Biol Psychiatry 60:951-956, 2006.
21. Pope HG, Jr., McElroy SL, Keck PE, Jr., Hudson JI: Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 48:62-68, 1991.
22. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (CCASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043, 2007.
23. Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R: Preliminary studies of the reliability and validity of the children's depression raitng scale. J Am Acad Child Adolesc Psychiatry 23:191-197, 1984.
24. Sandoval J, Echandia A: Behavioral Assessment System for Children. J School Psychol 32:419-425, 1994.
25. Schenkel LS, Marlow-O'Connor M, Moss M, Sweeney JA, Pavuluri MN: Theory of mind and social inference in children and adolescents with bipolar disorder. Psychol Med:1-10, 2008.
26. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
27. United States Food and Drug Administration, Center for Drug Evaluation and Research: Information for Healthcare Professionals: Suicidality and Antiepileptic Drugs. 1/31/2008; http://www.fda.gov/cder/drug/InfoSheets/HCP/ antiepilepticsHCP.htm/. Accessed February 5, 2008.
28. United States Food and Drug Administration, Center for Drug Evaluation and Research: Statistical review and Evaluation: Antiepileptic Drugs and Suicidality. 5/23/2008; http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008- 4372b1-01-FDA.pdf/. Accessed July 8, 2008.
29. Verrotti A, Trotta D, Morgese G, Chiarelli F: Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 17:367-373, 2002.
30. Wagner KD: Presentation at the American Academy of Child & Adolescent Psychiatry annual meeting, Boston Massachusetts, 2007.
31. Wagner KD, Weller EB, Carlson GA, Sachs G, Biederman J, Frazier JA, Wozniak P, Tracy K, Weller RA, Bowden C: An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 41:1224-1230, 2002.
32. Wechsler D: Wechsler Abbreviated Scale of Intelligence. San Antonio (Texas): The Psychological Corporation, 1999.
33. Wu A: Tietz Clinical Guide to Laboratory Tests, 4th ed. St Louis (Missouri): Saunders/Elsevier, 2006.
34. Wyllie E, Wyllie R, Rothner AD, Erenberg G, Cruse RP: Valproate-induced hyperammonemia in asymptomatic children. Cleve Clin Q 50:275-277, 1983.
35. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133:429-435, 1978.
36. Zaccara G, Cincotta M, Borgheresi A, Balestrieri F: Adverse motor effects induced by antiepileptic drugs. Epileptic Disord 6:153-168, 2004.